News | May 10, 2021
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Subscribe To Our Newsletter & Stay Updated
